Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: ABT
  • CUSIP: 00282410
Key Metrics:
  • Previous Close: $43.53
  • 50 Day Moving Average: $44.46
  • 200 Day Moving Average: $41.65
  • 52-Week Range: $36.76 - $45.84
  • Trailing P/E Ratio: 45.96
  • Foreward P/E Ratio: 15.99
  • P/E Growth: 1.57
  • Market Cap: $76.33B
  • Outstanding Shares: 1,727,997,000
  • Beta: 0.97
  • Net Margins: 6.71%
  • Return on Equity: 15.74%
  • Return on Assets: 8.27%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.25%

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 4 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $48.90 (10.81% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/22/2017Cowen and CompanyReiterated RatingOutperform$48.00MediumView Rating Details
4/20/2017Barclays PLCBoost Price TargetOverweight -> Overweight$50.00 -> $52.00LowView Rating Details
4/19/2017Morgan StanleyReiterated RatingEqual Weight$42.00LowView Rating Details
4/18/2017Jefferies Group LLCLower Price TargetBuy$52.00 -> $50.00MediumView Rating Details
4/18/2017Stifel NicolausReiterated RatingBuy$49.00MediumView Rating Details
3/14/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$48.00MediumView Rating Details
3/1/2017Royal Bank of CanadaBoost Price TargetOutperform$46.00 -> $50.00N/AView Rating Details
9/19/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016Goldman Sachs Group IncLower Price TargetNeutral$44.00 -> $40.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
5/27/2015Evercore Partners Inc.Initiated CoverageBuy$54.00N/AView Rating Details
5/26/2015Evercore ISIInitiated CoverageBuy$54.00N/AView Rating Details
(Data available from 4/24/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE:ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20172$0.60$0.61$0.61
Q3 20172$0.64$0.68$0.66
Q4 20172$0.72$0.73$0.73
Q1 20181$0.56$0.56$0.56
Q2 20181$0.71$0.71$0.71
Q3 20181$0.74$0.74$0.74
Q4 20181$0.84$0.84$0.84
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Next Dividend:5/15/2017
Annual Dividend:$1.06
Dividend Yield:2.40%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:113.98% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.41% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE:ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoAbbott Laboratories: Constantly Adapting For Enduring Success - April 24 at 11:18 AM logoQ3 2017 EPS Estimates for Abbott Laboratories Cut by Leerink Swann (ABT) - April 24 at 8:44 AM logoAbbott Laboratories (ABT) Receiving Somewhat Positive Media Coverage, Study Shows - April 23 at 7:32 AM logoCowen and Company Reiterates Outperform Rating for Abbott Laboratories (ABT) - April 22 at 7:14 AM logoLeerink Swann Comments on Abbott Laboratories' FY2021 Earnings (ABT) - April 21 at 6:02 PM logoFY2019 EPS Estimates for Abbott Laboratories (ABT) Increased by Analyst - April 21 at 5:37 PM logoWilliam Blair Weighs in on Abbott Laboratories' FY2017 Earnings (ABT) - April 21 at 2:30 PM logoAbbott Laboratories Target of Unusually Large Options Trading (ABT) - April 21 at 7:09 AM logoAbbott Laboratories (ABT) Tops Q1 Earnings & Sales Estimates - Nasdaq - April 21 at 1:39 AM logoCowen Reiterates Outperform Rating and $48 PT on Abbott Labs ... - - April 20 at 3:17 PM logoAbbott Labs (ABT) PT Raised to $52 at Barclays Following 1Q Report - - April 20 at 3:17 PM logoEdited Transcript of ABT earnings conference call or presentation 19-Apr-17 1:00pm GMT - April 20 at 3:17 PM logoCompany News for April 20, 2017 - April 20 at 3:17 PM logo[$$] GTCR Forms Medical-Device Platform - April 20 at 3:17 PM logoLPC: US healthcare lending rouses from policy-induced sedation - April 20 at 3:17 PM logoAbbott Laboratories (ABT) PT Raised to $52.00 at Barclays PLC - April 20 at 1:34 PM logoAbbott Laboratories (ABT) to Post Q1 2017 Earnings of $0.43 Per Share, Jefferies Group Forecasts - April 20 at 10:11 AM logoAbbott Laboratories (ABT) Receives Daily Media Sentiment Rating of 0.11 - April 20 at 7:31 AM logoEarnings Reaction History: Abbott Laboratories, 50.0% Follow ... - Nasdaq - April 20 at 1:20 AM logoAbbott Laboratories' (ABT) Equal Weight Rating Reaffirmed at Morgan Stanley - April 19 at 8:10 PM logoFY2018 EPS Estimates for Abbott Laboratories Raised by Jefferies Group (ABT) - April 19 at 4:48 PM logoAbbott Laboratories' (ABT) CEO Miles White on Q1 2017 Results - Earnings Call Transcript - April 19 at 3:16 PM logoAbbott Reports First-Quarter 2017 Results - April 19 at 3:16 PM logoAbbott Labs beats Street on top and bottom line - April 19 at 3:16 PM logoAbbott shares rise 2.5% after first-quarter earnings, profit beats - April 19 at 3:16 PM logoMerger Challenges, FDA Concerns Push Abbott Shares Down Despite Strong First Quarter - April 19 at 3:16 PM logoAbbott's profit rises 33 percent after St. Jude Medical deal - April 19 at 3:16 PM logoAbbott Laboratories (ABT) Tops Q1 Earnings & Sales Estimates - April 19 at 3:16 PM logoStocks to Watch: Morgan Stanley, IBM, Abbott Labs - April 19 at 3:16 PM logoAbbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device - April 19 at 3:16 PM logoAbbott sees Alere as challenging 'fixer-upper' after revised deal - April 19 at 3:16 PM logoAbbott Laboratories (ABT) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS - April 19 at 2:20 PM logoWilliam Blair Weighs in on Abbott Laboratories' Q2 2017 Earnings (ABT) - April 19 at 9:24 AM logoAbbott Laboratories (ABT) Issues FY17 Earnings Guidance - April 19 at 9:19 AM logoAbbott posts 29.7% rise in quarterly sales - April 19 at 8:36 AM logoAbbott beats Street 1Q forecasts - April 19 at 8:14 AM logoAbbott's 1Q results top Wall Street's expectations - April 19 at 8:14 AM logoAbbott Labs: What To Look For In Q1 Earnings - April 19 at 5:46 AM logoAbbott-Alere Deal To Go Ahead - April 19 at 5:46 AM logoCarson Block Says There’s Temptation to Short Abbott - April 19 at 5:46 AM logoAbbott & Alere: Back Together Again - April 19 at 5:46 AM logoAbbott Laboratories’ 1Q17 Earnings: What to Expect - April 19 at 5:46 AM logoFY2021 Earnings Estimate for Abbott Laboratories Issued By Jefferies Group (ABT) - April 18 at 7:20 PM logoCompany News for April 18, 2017 - April 18 at 3:17 PM logo5 Stocks with Great Earnings Charts - April 18 at 3:17 PM logoAbbott Laboratories (ABT) Stock Rating Reaffirmed by Jefferies Group LLC - April 18 at 12:35 PM logoAbbott Laboratories' (ABT) "Buy" Rating Reaffirmed at Stifel Nicolaus - April 18 at 11:49 AM logoAbbott Laboratories (ABT) Given Consensus Rating of "Buy" by Analysts - April 18 at 8:44 AM logo[$$] Cyber Insurance Becomes a Must for More Manufacturers - April 18 at 5:27 AM logoCowen Reiterates Outperform Rating and $48 PT on Abbott Labs (ABT); 'ABT/STJ/ALR Combined Entity Finalized' at ... - - April 17 at 3:15 PM


Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 17th. Shareholders of record on Friday, April 14th will be paid a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Tuesday, April 11th.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, April, 19th. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.05. The firm had revenue of $6.34 billion for the quarter, compared to analysts' expectations of $6.16 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. Abbott Laboratories's revenue was up 29.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.41 EPS.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY17 earnings guidance on Wednesday, April, 19th. The company provided earnings per share (EPS) guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.45.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

17 brokers have issued twelve-month price targets for Abbott Laboratories' shares. Their forecasts range from $42.00 to $55.00. On average, they anticipate Abbott Laboratories' share price to reach $48.90 in the next year.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 13,259,599 shares, a decrease of 15.9% from the February 28th total of 15,760,489 shares. Based on an average daily trading volume, of 7,173,137 shares, the days-to-cover ratio is currently 1.8 days.

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vontobel Asset Management Inc. (0.24%), Harding Loevner LP (0.15%), Bank of Montreal Can (0.14%), Chevy Chase Trust Holdings Inc. (0.09%), United States Steel & Carnegie Pension Fund (0.09%) and First Manhattan Co. (0.09%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Vontobel Asset Management Inc., CWM LLC, Harding Loevner LP, Factory Mutual Insurance Co., First National Bank of Omaha, Charter Trust Co., Bridges Investment Counsel Inc. and Cape Cod Five Cents Savings Bank. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Bank of Montreal Can, Foundry Partners LLC, Granite Investment Advisors LLC, Chevy Chase Trust Holdings Inc., Candriam Luxembourg S.C.A., National Pension Service and Nisa Investment Advisors LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abbott Laboratories stock cost?

One share of Abbott Laboratories stock can currently be purchased for approximately $44.13.

Abbott Laboratories (ABT) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by Staff